The efficacy and safety of disitamab vedotin plus immunotherapy in locally advanced or metastatic solid tumors: a systematic review and meta-analysis

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-02-25
DOI
https://doi.org/10.3389/fimmu.2026.1763542
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The efficacy and safety of disitamab vedotin plus immunotherapy in locally advanced or metastatic solid tumors: a systematic review and meta-analysis

Xicheng Zhang, Qi Wei, Jie Feng, Tiancheng Liu et al.
Frontiers in Immunology
HER2/EGFR in Cancer Research
article

The efficacy and safety of disitamab vedotin plus immunotherapy in locally advanced or metastatic solid tumors: a systematic review and meta-analysis

Xicheng Zhang, Qi Wei, Jie Feng, Tiancheng Liu, Jianjun Ye, Xinyang Liao, Lei Zheng, Qihao Wang, Zeyu Chen, Yige Bao
article en

Abstract

No abstract available for this paper.
Frontiers in ImmunologyVol. 17
Sichuan University (CN), West China Hospital of Sichuan University (CN), State Key Laboratory of Oral Diseases
Good health and well-being
Openalex Percentile: Top 42%
HER2/EGFR in Cancer Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.